Highlights
- •This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed.
- •SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed.
- •Readers should pay attention to the overstatements in preprints of COVID-19 RCT.
medRxiv COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv.https://connect.medrxiv.org/relate/content/181. Accessed July 3, 2020.
- Shokraneh F.
PubMed | Cochrane Work. https://work.cochrane.org/pubmed. Accessed June 3, 2020.
- Ye Y.

medRxiv | PubMed | Total | Risk differences (%) and confidence intervalsg | |
---|---|---|---|---|
N = 13 | N = 16 | N = 29 | ||
Number of participants of full analysis set | 81 (42–92) | 115 (54.5–260.5) | 86 (50–199) | .24h |
Without the information of trial registration | 0 (0%) | 3 (19%) | 3 (10%) | 19 [−0.37 to 38] |
Inconsistent with trial registrationa | 8 (62%) | 4 (30%) | 12 (46%) | −31 [−67 to 5.7] |
Referring limitations in abstracts | ||||
Present | 1 (8%) | 4 (25%) | 5 (17%) | 19 [−7.7 to 46] |
Without an abstract | 0 (0%) | 1 (6%) | 1 (3%) | |
High or some concerns of risk of biasb | ||||
Randomization process | 3 (23%) | 5 (31%) | 8 (28%) | 8.2 [−24 to 40] |
Deviations from intended interventions | 3 (23%) | 4 (25%) | 7 (24%) | 1.9 [−29 to 33] |
Missing outcome data | 2 (15%) | 0 (0%) | 2 (7%) | −15 [−35 to 4.2] |
Measurement of the outcome | 6 (46%) | 6 (38%) | 13 (45%) | −8.7 [−45 to 27] |
Selection of the reported result | 9 (69%) | 8 (50%) | 17 (60%) | −19 [−54 to 16] |
Overall Bias | 10 (77%) | 11 (70%) | 21 (72%) | −8.2 [−40 to 24] |
SPINc in titles (n = 11)d | ||||
Present | 1 (20%) | 0 (0%) | 1 (3%) | −20 [−55 to 15] |
SPINc in conclusions (n = 11) d | ||||
present | 4 (80%) | 1 (17%) | 5 (45%) | −63 [−100 to −17] |
Number of SNS sharee | .09h | |||
0 | 3 (23%) | 2 (13%) | 5 (17%) | |
10> ≥1 | 1 (8%) | 1 (6%) | 2 (7%) | |
100> ≥10 | 3 (23%) | 1 (6%) | 2 (14%) | |
1000> ≥100 | 5 (38%) | 5 (31%) | 10 (34%) | |
10,000> ≥1000 | 1 (8%) | 4 (25%) | 5 (17%) | |
≥10,000 | 0 (0%) | 3 (19%) | 3 (10%) | |
Number of citationsf | .17h | |||
0 | 7 (54%) | 3 (19%) | 10 (34%) | |
10> ≥1 | 1 (8%) | 5 (31%) | 6 (21%) | |
100> ≥10 | 4 (31%) | 5 (31%) | 9 (31%) | |
≥100 | 1 (8%) | 3 (19%) | 4 (14%) |
1. Discussion
Compliance with ethical stantards
Author contributions
Funding
Declaration of Competing Interest
Acknowledgement
Appendix. Supplementary materials
- application 1
- application 1
References
Kataoka Y., Oide S., Ariie T., Tsujimoto Y., Furukawa T.A.. Quality of COVID-19 research in preprints: a meta-epidemiological study protocol. protocols.io.2020. doi:10.17504/protocols.io.bhm8j49w.
- Guidelines for reporting meta-epidemiological methodology research.Evid Based Med. 2017; 22: 139-142https://doi.org/10.1136/ebmed-2017-110713
medRxiv COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv.https://connect.medrxiv.org/relate/content/181. Accessed July 3, 2020.
- Keeping up with studies on covid-19: systematic search strategies and resources.BMJ. 2020; (Aprilm1601)https://doi.org/10.1136/bmj.m1601
PubMed | Cochrane Work. https://work.cochrane.org/pubmed. Accessed June 3, 2020.
- RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ. 2019; (August): l4898https://doi.org/10.1136/bmj.l4898
- Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.JAMA. 2010; 303: 2058https://doi.org/10.1001/jama.2010.651
- Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China.medRxiv. 2020; (January 202003.27.20044974)https://doi.org/10.1101/2020.03.27.20044974